Bluebird bio Inc Asset Resilience Ratio
Bluebird bio Inc asset resilience ratio. Bluebird bio Inc (BLUE) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Bluebird bio Inc (BLUE) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Bluebird bio Inc (2011–2023)
Asset resilience ratio of Bluebird bio Inc from 2011 to 2023. This chart shows how Bluebird bio Inc's Asset Resilience Ratio has changed over time. Read Bluebird bio Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Bluebird bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Bluebird bio Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Bluebird bio Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Bluebird bio Inc Industry Peers by Asset Resilience Ratio
Compare Bluebird bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Bluebird bio Inc Asset Resilience Ratio by Year (2011–2023)
Bluebird bio Inc asset resilience ratio by year from 2011 to 2023. The table below shows the annual Asset Resilience Ratio data for Bluebird bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $619.16 Million | -- |
| 2022-12-31 | 12.13% | $67.32 Million | $554.90 Million | -11.17pp |
| 2021-12-31 | 23.30% | $138.34 Million | $593.79 Million | -23.50pp |
| 2020-12-31 | 46.80% | $833.55 Million | $1.78 Billion | +1.69pp |
| 2019-12-31 | 45.11% | $779.25 Million | $1.73 Billion | +1.29pp |
| 2018-12-31 | 43.82% | $982.73 Million | $2.24 Billion | +15.85pp |
| 2017-12-31 | 27.97% | $531.60 Million | $1.90 Billion | -10.08pp |
| 2016-12-31 | 38.05% | $425.49 Million | $1.12 Billion | +2.77pp |
| 2015-12-31 | 35.29% | $353.68 Million | $1.00 Billion | +12.71pp |
| 2014-12-31 | 22.58% | $125.71 Million | $556.74 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $224.39 Million | -- |
| 2011-12-31 | 11.34% | $3.51 Million | $30.92 Million | -- |
About Bluebird bio Inc
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disea… Read more